The impact of sickle cell disease and its treatment on ovarian reserve in reproductive-aged Black women

Br J Haematol. 2024 Aug;205(2):674-685. doi: 10.1111/bjh.19582. Epub 2024 Jun 6.

Abstract

We compared serum anti-Mullerian hormone (AMH) levels in women with sickle cell disease (SCD) (n = 152) to those of Black comparison women (n = 128) between the ages of 20 and 45 years and evaluated the impact of hydroxyurea (HU) and iron overload on ovarian reserve in those with SCD. SCD treatment was abstracted from medical records. Linear regression models were fit to examine the relationship between log(AMH) and SCD, adjusting for age. The analysis was repeated to account for HU use (current, previous, never) and iron overload (ferritin ≥1000 ng/mL vs. <1000 ng/mL). AMH estimates among women with SCD were lower than those among comparison women (2.23, 95% confidence interval [CI] 1.80-2.76 vs. 4.12, 95% CI 3.11-5.45, respectively). Women with SCD who were currently using HU had 63% lower (95% CI 43-76) AMH values than comparison women; those with SCD with prior or no HU use also had lower AMH estimates than comparison women, but the difference was less pronounced. There were no differences in predicted AMH values among women with SCD for those with and without iron overload. Women with SCD and low AMH may have a shorter reproductive window and may benefit from referral to a reproductive specialist.

Keywords: blood transfusion; hydroxyurea; iron overload; ovarian reserve; sickle cell disease.

MeSH terms

  • Adult
  • Anemia, Sickle Cell* / blood
  • Anemia, Sickle Cell* / complications
  • Anemia, Sickle Cell* / drug therapy
  • Anti-Mullerian Hormone* / blood
  • Black or African American
  • Female
  • Humans
  • Hydroxyurea* / therapeutic use
  • Iron Overload / blood
  • Iron Overload / drug therapy
  • Iron Overload / etiology
  • Middle Aged
  • Ovarian Reserve*
  • Young Adult

Substances

  • Anti-Mullerian Hormone
  • Hydroxyurea